HIV-1 Virologic Suppression With TMB-365 and TMB-380 Antibodies Trial
Phase 2
75
about 1.7 years
18+
10 sites in CA, FL, NV +2
About this study
This trial is testing whether a combination of antibodies, TMB-365 and TMB-380, can maintain viral suppression in people with HIV who are no longer taking oral medications. Participants will receive either an infusion of the antibodies every 8 weeks or continue daily oral medication for 48 weeks. Researchers will compare these two approaches to see which one is more effective at keeping the virus under control.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take Baseline ART
- 2.Take TMB-365
- 3.Take TMB-380
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
intravenous, oral
Secondary: Pharmacokinetic profile of TMB-365, Pharmacokinetic profile of TMB-380
Immune, Infectious